Gene therapy breakthrough: one dose may help babies with rare muscle disease
NCT ID NCT03505099
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a single dose of Zolgensma gene therapy in 30 infants diagnosed with spinal muscular atrophy (SMA) before symptoms appeared. The goal was to see if the treatment helps them reach motor milestones like sitting or standing alone. The therapy delivers a working copy of the missing SMN gene to stop muscle weakness from progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
onasemnogene abeparvovec (Zolgensma) gene therapy
What this could lead to
If successful, this one-time gene therapy could help infants with spinal muscular atrophy achieve key motor skills like sitting and standing, potentially preventing severe muscle weakness.
What could go wrong
This is a small, early-phase study (30 infants) and results may not apply to all SMA types. Long-term effects and risks, such as liver toxicity or immune reactions, are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Canada Childrens Hospital of Eastern Ontario
Ottawa, Ontario, K1H8L1, Canada
-
Centre Hospitalier Régional Hôpital La Citadelle
Liège, 4000, Belgium
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Medical Center Dallas
Dallas, Texas, 75235, United States
-
Clinic for Special Children
Strasburg, Pennsylvania, 17579, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
David Geffen School of Medicine at UCLA
Los Angeles, California, 90095, United States
-
Great Ormond Street Hospital for Children NHS Foundation Trust
London, WC1N 3JH, United Kingdom
-
Helen DeVos Children's Hospital
Grand Rapids, Michigan, 49503, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Nemours Children's Hospital
Orlando, Florida, 32827, United States
-
St. Louis Children's Hospital
St Louis, Missouri, 63110, United States
-
Sydney Children's Hospital
Randwick, New South Wales, 2145, Australia
-
Tokyo Women's Medical
Tokyo, Japan
-
University Hospital and UW Health Clinics
Madison, Wisconsin, 53792, United States